Trellus Health reports operational, commercial progress
By Josh White
Date: Tuesday 03 Feb 2026
(Sharecast News) - Trellus Health reported continued operational and commercial progress in a business update on Tuesday, highlighting growing momentum in its clinical trials vertical alongside ongoing cost control and funding initiatives.
The AIM-traded healthcare company said it had secured two new 12-month commercial contracts with global contract research organisations during the second half of 2025.
In October, Trellus entered into an agreement with ICON to support recruitment and enrolment optimisation for a mid-stage immunology and inflammation trial sponsored by Takeda, with revenues comprising an upfront fee, monthly management fees and milestone-based payments.
The programme was now being launched at agreed trial sites.
Later the same month, the company signed a second 12-month contract with PSI to deploy its 'TrialSet' solution across two late-stage immunology and inflammation trials sponsored by Sanofi, marking its second commercial CRO contract since the product's launch.
Trellus said implementation was underway and the programme was expected to be fully launched by the middle of the first quarter.
In addition, the group said it was continuing to support a phase two inflammatory bowel disease trial under its licensing agreement with AstraZeneca and had been granted preferred vendor status by both ICON and PSI, which it said should help streamline future contracting and improve access to pharmaceutical sponsors.
Outside clinical trials, Trellus said its collaboration with Johnson & Johnson Health Care Systems, signed in January last year, continued to progress, with pilot engagement and satisfaction metrics achieved and enrolment channels broadened in mid-January.
The company also renewed its agreement with Pfizer in the second quarter of 2025 to license patient support educational content for Pfizer's IBD digital application, with discussions ongoing around a potential expansion ahead of a renewal expected in 2026.
On the platform side, Trellus said it was expanding TrialSet as a condition-agnostic solution beyond IBD into additional therapeutic areas, while continuing to enhance its Trellus
'Elevate' platform.
Work was ongoing to achieve GDPR compliance, alongside maintenance of its SOC 2 Type II certification.
The firm said it expected revenue for the year ended 2025 to be around $545,000 and added that it had reduced monthly cash burn to about $400,000, partly offset by recurring management fees generated in the second half of the year.
Trellus said it had secured a £5m convertible facility with Alumni Capital, approved by shareholders in January, and believed the initial tranches totalling £737,500 in gross principal would extend its cash runway into late in the first quarter.
Discussions on additional funding options were ongoing.
"We are very pleased with the progress across our verticals during the second half of the year," said chief executive Dr Marla Dubinsky.
"Whilst reducing our monthly burn by 23% since the beginning of 2025, we successfully executed our patient support programme with J&J and developed and launched TrialSet.
"We continue to manage costs and working capital carefully and are encouraged by the growing validation of our differentiated, behavioural science-based approach.
"We remain focused on progressing commercial discussions and look forward to updating the market on further developments."
At 1254 GMT, shares in Trellus Health were down 27.47% at 0.69p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN